San Diego–based CareFusion announced this week that it has finalized much of its planned $500 million purchase of Vital Signs from GE Healthcare.
The acquisition of the $250-million-a-year Vital Signs doubles the size of CareFusion's disposable device business while broadening its involvement in the anesthesia segment, which already was an important business for the firm. The acquisition will also help the company expand its inventory of custom-made products while broadening its business outside of the United States, according to company's CEO, Kieran Gallahue. At present, the substantial portion of the company's business came from the sales of specialty disposables.
"We are in a better position to serve customers in this large, global and growing market with a broader product portfolio and complementary expertise in respiratory and anesthesia care," Gallahue said in a news release.
At present, CareFusion has already paid $470 million to GE Healthcare for the purchase. The remainder will be paid pending regulatory review and customary closing conditions involving remaining Vital Signs international operations.
The completed acquisition includes operations in the U.S., China and certain other geographies.
Before the acquisition, CareFusion's products were used by more than 25,000 customers located throughout the world. Its customers include hospitals, insurers, surgical centers, outpatient centers, and governments.
